Today in our #SFBay newsletter: $ALLO Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases; $ALLK Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

Subscribe to our daily newsletter for more:
#SFBay #ALLO #ALLK